Drug Profile
HG 3001
Alternative Names: HG 3001Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator HitGen
- Class Antineoplastics; Small molecules
- Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Liver cancer; Lung cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Breast-cancer in China (PO)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Liver-cancer in China (PO)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Lung-cancer in China (PO)